A newly submitted clinical abstract utilizes MyoStrain to detect the cardiotoxic effects of Carfilzomib, a cancer therapy drug used in treating patients diagnosed with multiple myeloma.Conducted at Heidelberg University Hospital in Germany as part of an ongoing...
Last weekend, the Myocardial Solutions (MSI) team attended the European Society of Cardiology (ESC) Congress 2019 to further the discussion of MyoStrain as a unique clinical tool for helping physicians proactively detect, monitor and manage heart failure. The ESC Congress took place from August...
A new article on MyoStrain has been published in Nature Research’s recent Scientific Reports issue. Based upon an ongoing study conducted at German Heart Center Berlin (Charité University Medical Center Berlin), the article evaluates MyoStrain’s consistency in the acquisition of left ventricular...
A new article demonstrating the significant cost savings that could be achieved using MyoStrain to detect and manage early heart failure was published in Health Economics Review. The article, authored by Avalon Health Economics (Avalon), compares MyoStrain to Echocardiography (ECHO), the most...
The PROactive evaluation of function to Avoid Cardio-Toxicity (PROACT; NCT03862131) clinical trial has started at Washington University School of Medicine and Yale New Haven Hospital with patients receiving baseline MyoStrain exams before chemotherapy treatment. The study will evaluate the...
